VIVIMED LABS
|
|
BOM : 532660     NSE : VIVIMEDLAB     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : Average [>25% and <50%] |
Jun 24,2022 |
Price(EOD): ₹ 10.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 88.70 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
VIVIMED LABS | 27.1% | -17.1% | -65.3% |
SUN PHARMACEUTICAL INDUSTRIES | 2.4% | -8.5% | 23.8% |
DIVIS LABORATORIES | 4.3% | 6.7% | -12.6% |
DR REDDYS LABORATORIES | 3.8% | 0% | -18.7% |
CIPLA | 0.8% | -3.2% | -2.4% |
GLAND PHARMA | 2.4% | -7.3% | -17.9% |
PIRAMAL ENTERPRISES | 3.9% | -11% | -33.4% |
CADILA HEALTHCARE | 5.7% | -5.1% | -45.1% |
TORRENT PHARMACEUTICALS | 4.1% | -0.9% | -2.5% |
FUNDAMENTAL ANALYSIS OF VIVIMED LABS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF VIVIMED LABS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-
P/E Calculated based on EPS of -13.16
[ Mar2020 - Consolidated Results ] 0.19
P/B Calculated based on Book Value of 56.85
[ Mar2020 - Consolidated Results ] 0.37
P/S Calculated based on Revenues of 237.287 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA NA (-ve EV) 11% |
SHARE PRICE MOMENTUM OF VIVIMED LABS
VIVIMED LABS vs SENSEX
DEBT OF VIVIMED LABS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
- 0.59 0.65 0.41 |
- 1.18 1.05 0.74 |
[Last Annual Data : Mar2020]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF VIVIMED LABS
Pledged Promoter Shares |
40.02 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF VIVIMED LABS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
8.16% 85.14% 34.48% 22.58% |
56.78% 93.37% 44.39% 33.24% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
VIVIMED LABS related INDICES
You may also like the below Video Courses
FAQ about VIVIMED LABS
Is VIVIMED LABS good for long term investment?
As on Jun 24,2022, the Fundamentals of VIVIMED LABS look Poor and hence it may not be good for long term investment ! See Financial Performance of VIVIMED LABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is VIVIMED LABS UnderValued or OverValued?
As on Jun 24,2022, VIVIMED LABS is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of VIVIMED LABS ?
As on Jun 24,2022, the Intrinsic Value of VIVIMED LABS is Rs. 9.63 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -10.24
Fair Value [Median EV / Sales Model] : Rs. -6.22
Fair Value [Median Price / Sales Model] : Rs. 9.63
Median Fair Value of VIVIMED LABS : Rs. 9.63
Is VIVIMED LABS trading at a Premium or Discount?
As on Jun 24,2022, VIVIMED LABS is trading at a Premium of 11% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
